Modern drug discovery and development require the training of scientists who understand the molecular, physiological and quantitative basis of drug action and specificity, and who can apply modern technologies and concepts to the development of novel therapeutic strategies. This multidisciplinary doctoral training program in the Pharmacological Sciences is designed to help meet that demand by preparing students for biomedical research careers in schools of medicine, dentistry and pharmacy, in research institutes, and in governmental or industrial laboratories. The most important component of training is laboratory research, first as a series of research rotations, then in the dissertation laboratory. This training is complemented by a core course that integrates the theoretical and experimental foundations of modern biological sciences;core courses in pharmacology that emphasize quantitative analysis of drug action, pharmacokinetics, drug disposition, biostatistics and experimental design;advanced courses in specialty areas;seminar courses and journal clubs. Emphasis throughout is placed on development and refinement of communication and analytical skills. The 43 training faculty represent 8 basic science and 6 clinical departments or Centers at Emory, and two Departments at Georgia Tech., providing a wealth of diverse research training opportunities. Their research foci can be loosely grouped in four broad areas: transmembrane signaling, cell growth control and molecular recognition, substance abuse and behavioral pharmacology, and molecular toxicology. This Program currently supports six students each year, who are selected mainly from a pool of approximately 35 eligible students in the Molecular and Systems Pharmacology (MSP) Program. Six slots are requested in this renewal. Graduates will have acquired broad familiarity with pharmacology, knowledge in depth in the area of dissertation research, and the technical, communicative and analytical skills necessary to pursue an independent research career. Students graduate an average of 5.2 years after matriculation. The research conducted by the trainees in this program will advance our knowledge of disease processes and contribute to development of novel and improved therapeutic strategies that will benefit the health of our citizens. By preparing young scientists to contribute to and lead the nation's efforts in these areas, this training program will help to ensure that our ability to improve the nation's health remains strong in the future.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Institutional National Research Service Award (T32)
Project #
5T32GM008602-14
Application #
7898937
Study Section
National Institute of General Medical Sciences Initial Review Group (BRT)
Program Officer
Okita, Richard T
Project Start
1996-07-01
Project End
2012-06-30
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
14
Fiscal Year
2010
Total Cost
$262,406
Indirect Cost
Name
Emory University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Regan, Michael C; Grant, Timothy; McDaniel, Miranda J et al. (2018) Structural Mechanism of Functional Modulation by Gene Splicing in NMDA Receptors. Neuron 98:521-529.e3
Bai, Renren; Sun, Jian; Liang, Zhongxing et al. (2018) Anti-inflammatory hybrids of secondary amines and amide-sulfamide derivatives. Eur J Med Chem 150:195-205
Salam, Akram M; Quave, Cassandra L (2018) Targeting Virulence in Staphylococcus aureus by Chemical Inhibition of the Accessory Gene Regulator System In Vivo. mSphere 3:
Squires, Katherine E; MontaƱez-Miranda, Carolina; Pandya, Rushika R et al. (2018) Genetic Analysis of Rare Human Variants of Regulators of G Protein Signaling Proteins and Their Role in Human Physiology and Disease. Pharmacol Rev 70:446-474
Fernandes, Jolyn; Chandler, Joshua D; Liu, Ken H et al. (2018) Putrescine as indicator of manganese neurotoxicity: Dose-response study in human SH-SY5Y cells. Food Chem Toxicol 116:272-280
Wells, Gordon; Yuan, Hongjie; McDaniel, Miranda J et al. (2018) The GluN2B-Glu413Gly NMDA receptor variant arising from a de novo GRIN2B mutation promotes ligand-unbinding and domain opening. Proteins 86:1265-1276
Bian, Xuehai; Liang, Zhongxing; Feng, Amber et al. (2018) HDAC inhibitor suppresses proliferation and invasion of breast cancer cells through regulation of miR-200c targeting CRKL. Biochem Pharmacol 147:30-37
Hudson, William H; Vera, Ian Mitchelle S de; Nwachukwu, Jerome C et al. (2018) Cryptic glucocorticoid receptor-binding sites pervade genomic NF-?B response elements. Nat Commun 9:1337
Brown, Harrison C; Zakas, Philip M; George, Stephan N et al. (2018) Target-Cell-Directed Bioengineering Approaches for Gene Therapy of Hemophilia A. Mol Ther Methods Clin Dev 9:57-69
Gibb, Alasdair J; Ogden, Kevin K; McDaniel, Miranda J et al. (2018) A structurally derived model of subunit-dependent NMDA receptor function. J Physiol 596:4057-4089

Showing the most recent 10 out of 176 publications